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1. Introduction  
Most drugs have effects attributed to actions at sites other than those that are intended. In 
many cases these off-target effects have adverse consequences, though in some instances 
these effects may be neutral or even beneficial. Many off-target effects involve either direct 
or indirect actions on ion channels. Hence, electrophysiological approaches can be employed 
to screen drugs for effects on ion channels and thereby predict their off-target actions. The 
pharmaceutical industry routinely uses cellular expression systems and cloned channels to 
quickly screen thousands of compounds to eliminate those that have well known adverse 
ion channel effects, such as inhibition of the Kv11.1 potassium channel encoded by the 
human Ether-à-go-go related gene (hERG). However, these methods are not well-suited to 
predicting many other off-target effects mediated by actions on ion channels natively 
expressed in specific tissues. We have employed a more directed electrophysiological 
approach to evaluate a small number of compounds (e.g. drugs with known or predicted 
adverse effects) to identify ion channel targets that might explain their actions. This chapter 
will describe this approach in some detail and illustrate its use with some specific examples. 
2. Approach 
Our general approach to evaluating ion channel effects of a specific drug on a particular cell 
type involves the following steps: 
2.1 Establish an adequate single cell physiological model to evaluate the drug of 
interest  
While expression systems such as the human embryonic kidney (HEK) cell line or Chinese 
hamster ovary (CHO) cell line over-expressing individual ion channels are useful tools for 
initial drug screening they may not adequately reflect the functional roles of ion channels in 
their native tissues. Immortalized or primary cell culture models that retain expression of 
the same ion channels that are natively expressed in the tissue under investigation should be 
considered. Some examples include neonatal cardiomyocytes for studying cardiac ion 
channel function (Markandeya et al., 2011), rat superior cervical ganglion (SCG) neurons for 
natively expressed neuronal ion channels (Kim et al., 2011; Zaika et al., 2011), and embryonic 
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rat aortic (A7r5 and A10) cell lines for investigating vascular smooth muscle 
electrophysiology (Roullet et al., 1997; Brueggemann et al., 2005; Brueggemann et al., 2007). 
The advantages of using cultured cells compared with freshly dissociated cells from the 
native tissue include their accessibility, ease of maintenance, high experimental 
reproducibility, and susceptibility to molecular interventions. However, there are also 
disadvantages in the use of cultured cells. In particular, the expression pattern of ion 
channels, receptors, and signaling proteins may differ between cultured cells and native 
tissues due to differences in proliferative phenotype, absence of surrounding tissues in cell 
culture and developmental stage from which the cells were derived. Hence, the results 
obtained using cultured cells should be interpreted with caution and, whenever possible, 
supplemented by studies performed on freshly dispersed cells and/or by functional assays 
using intact tissues or live animals.         
2.2 Select the patch-clamp mode (e.g. ruptured or perforated patch) for 
electrophysiological recording 
Selection of the patch-clamp mode of recording is generally based on the known properties 
of the ion channels to be studied. Important considerations include their regulation by 
phosphatidylinositol 4,5-bisphosphate (PIP2) and soluble second messengers. The open state 
of many types of ion channels is known to be stabilized by membrane PIP2 (Hilgemann & 
Ball, 1996; Loussouarn et al., 2003; Zhang et al., 2003; Bian & McDonald, 2007; Rodriguez et 
al., 2010; Suh et al., 2010). With conventional (ruptured) patch-clamp recording, the levels of 
PIP2 decrease over time, which can cause irreversible rundown of the currents. Inclusion of 
Mg-ATP in the internal solution may slow rundown of the PIP2-dependent currents in 
excised or ruptured patch recordings (Ribalet et al., 2000), but only the use of the perforated 
patch configuration enables extended recording of stable whole cell currents for tens of 
minutes. Regulation of channels via the actions of soluble second messengers may be altered 
in the ruptured patch configuration as cytosolic solutes may be lost by dialysis into the 
relatively large volume of the pipette solution. Use of the perforated patch configuration 
prevents dialysis of signaling molecules and loss of PIP2 from the membrane. But the 
ruptured patch-clamp configuration is technically less demanding and so is often preferable 
if signaling mechanisms are not a concern or if the channels of interest are less dependent on 
PIP2 for their activity. Ruptured patch techniques are commonly used for recording currents 
from voltage-gated sodium channels, Cav3 (T type) calcium channels, potassium channels of 
Kv1, Kv2, Kv3 and K2P families, cystic fibrosis transmembrane receptor (CFTR)-type 
chloride channels, TRPC family of non-selective cationic channels and ORAI1 store-operated 
channels. The ruptured patch mode also enables faster data collection, saving the 
investigator the extra 15-30 min required for patch perforation in each experiment.  
The choice of pore-forming agent used for patch perforation is often a matter of personal 
preference. Pores formed by amphotericin B and nystatin in the membrane under the patch are 
selectively permeable to monovalent ions (such as K+, Na+, Cs+, Cl-) preserving cytosolic Ca2+ 
and Mg2+ concentrations and all soluble cytosolic signaling molecules (Horn & Marty, 1988; 
Rae et al., 1991). Use of gramicidin for patch perforation also preserves intracellular Cl- 
concentration as gramicidin pores are impermeable to Cl- (Ebihara et al., 1995). It is possible to 
record stable currents for several hours in perforated-patch mode from a single cell when 
appropriate pipette and bath solution compositions are used with continuous bath perfusion.  
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When using the perforated-patch recording technique, attention should be paid to the value 
of access resistance achieved. The value of the access resistance (or series resistance as it is 
also known) will likely exceed pipette resistance by 2- to 5-fold and when current 
amplitudes are in the nanoampere range will introduce significant error into the true 
membrane voltage-clamped value. The amount of voltage error can be estimated by 
multiplying series resistance by current amplitude. If the error exceeds a few millivolts, 
series resistance compensation should be used. 
2.3 Determine the appropriate composition of the internal (pipette) and external (bath) 
solutions 
After choosing a physiological cell model that mimics as closely as possible cells in the intact 
tissue, it is logical to use intracellular and extracellular solutions with compositions similar 
to body fluids, at least for initial drug testing. Recipes for different extracellular 
physiological saline solutions (PSS) such as Krebs-Henseleit solution, Hank’s balanced salt 
solution (HBSS), artificial cerebral spinal fluid (CSF) are readily available in the relevant 
scientific literature. The pH of the external solution is typically 7.3-7.4. 
The composition of the internal (pipette) solution should also closely match known cytosolic 
ionic composition: high in K+ (usually in the range of 135-140 mM), low in Na+ (normally 
from 0-5 mM). The concentration of Cl- may vary depending on cell type. For many cultured 
cells, such as A7r5 cells, stable recordings are most easily obtained using relatively low  
[Cl-]in, in the range of 30-45 mM, in combination with large impermeable anions such as 
gluconate or aspartate to balance K+. For other cell types, including freshly dispersed 
smooth muscle cells, pipette solutions with 135-140 mM KCl are preferable. If the internal 
solution will be used in perforated patch-clamp mode, inclusion of Mg2+ and buffering of 
cytosolic Ca2+ is not required, as amphotericin and nystatin pores are impermeable to Ca2+ 
and Mg2+ (Horn & Marty, 1988; Rae et al., 1991).  
For ruptured patch recording, free Mg2+ concentration should be set within the range of 1-2 
mM and free Ca2+ concentration should be approximately 100 nM. To accomplish this, Ca2+ 
buffers such as EGTA, EDTA, or BAPTA should be included in the pipette solution. Free 
Ca2+ concentration will depend on the concentration of the buffers (usually 0.1-10 mM), their 
binding constants for Ca2+ and Mg2+ and the amounts of added Ca2+ and Mg2+. 
MAXCHELATOR is a series of programs freely available online 
(http://maxchelator.stanford.edu/) that can be used for determining the free Ca2+ 
concentration in the presence of Ca2+ buffers. Mg- or Na-ATP (1-5 mM) should also be 
included in the internal solution for ruptured patch recording. The range of pH for internal 
solutions may vary from 7.2-7.4, usually buffered with HEPES (1-10 mM). 
Attention should be paid to the osmolality of both internal and external solutions. 
Osmolality of body fluids is approximately 275-290 mOsM; the osmolality of the internal 
and external solutions should be measured with an osmometer, adjusted to the 
physiological range, and balanced (within 1 or 2 mOsM) between internal and external 
solutions.  
Use of approximately physiological external and internal solutions for patch-clamp 
experiments enables recording of a mix of ionic conductances for initial evaluation of drug 
effects on the cell type under investigation. 
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2.4 Use appropriate voltage clamp protocols (e.g. voltage steps or ramps) to record 
drug effects on total currents 
Design of the voltage protocol should be based on biophysical properties of the ion channels 
expressed in the cells under investigation. It is very useful for initial drug screening to select 
a holding voltage close to the resting membrane voltage measured or reported for that 
particular cell type. A voltage protocol designed to apply a family of long test voltage steps 
(1-5 s) in both negative and positive directions from the resting membrane voltage allows 
the investigator to record a mix of both rapidly and slowly activating/inactivating currents 
through voltage-dependent and voltage-independent ion channels. 
The time between voltage steps should be sufficient for channel deactivation.  
The stability of the measured currents should be established before testing the effects of 
drugs on the currents. For example, applying the same series of voltage steps should 
generate approximately equal currents on successive trials in the same cell. Voltage-ramp 
protocols can also be used to record instantaneous (voltage-independent) or rapidly 
activating currents; the ramp can be applied at regular intervals to monitor the stability of 
the currents over time. For slowly activating currents, use of a single voltage step applied at 
regular intervals is generally more appropriate for time course measurements.  
When stable recordings of total ionic conductances are achieved, it is possible to test the 
effects of a drug, usually applied at varying concentrations. Drugs may affect the 
amplitudes of the conductances and the kinetics of their responses to the applied voltage 
protocols as well as their voltage-dependence of activation. The drug effects are generally 
time-dependent and vary with drug dose in a reproducible manner. Careful evaluation of 
the drug effects on total membrane currents provides important clues to the types of ionic 
conductances that may be affected. It is then desirable to record the drug-targeted ionic 
conductances in isolation. 
2.5 Adjust recording conditions to isolate drug-sensitive currents 
To record specific currents among the mix of total cellular ionic conductances, a tailored 
voltage protocol should be used in combination with internal and external solutions and 
pharmacological approaches that are rationally chosen to enhance or maintain the current of 
interest while minimizing other conductances. The voltage protocol should reflect the 
specific biophysical properties of the channels under investigation. If the data are available, 
consider the voltage dependence of activation and time constants of activation, inactivation 
and deactivation of the currents. For example, store-operated currents are known to be 
inwardly-rectifying and highly Ca2+-selective, with fast Ca2+-dependent inactivation at 
negative voltages (Parekh & Putney, 2005). To isolate the highly Ca2+-selective store-
operated currents from other conductances, consider using an external solution containing 
10-20 mM Ca2+ and replacing all monovalent ions (K+, Na+ and Cl-) with impermeant ions 
such as N-methyl D-glucamine and aspartate. A voltage protocol comprised of a 0 mV 
holding voltage with 100 ms ramps from +100 to -100 mV can be applied every 5-20 s to 
record the time course of current activation in response to store depletion (often induced by 
dialyzing cells with EGTA- or BAPTA-containing pipette solution in ruptured patch mode 
or by application of thapsigargin or cyclopiazonic acid, which block the ability of the cells to 
sequester Ca2+ in the endoplasmic/sarcoplasmic reticulum (Brueggemann et al., 2006)).  
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In general, the isolation of broad classes of ionic conductances (i.e. Ca2+ currents, K+ 
currents, nonselective cation currents, or Cl- currents) may be achieved by using bath and 
pipette solutions containing ions that cannot permeate or that block the movement of ions 
through other classes of ion channels. For example, to record Ca2+ conductance in isolation, 
Cs+ can be used to replace K+ because it blocks most if not all K+ channels and thereby 
minimizes contributions of outward K+ currents to the recording. Similarly, replacing Cl- 
with aspartate, gluconate or sulfonate will minimize contributions of Cl- conductances.  
It is much more difficult to isolate ion currents within the same class. This may require the 
use of pharmacological agents that are selective for a particular class of channels. For 
example, if it is desired to isolated T-type Ca2+ current from L-type Ca2+ current, specific L-
type Ca2+ channel blockers like verapamil can be used. In this case, an alternative (or 
adjunct) approach is the use of the ruptured patch mode, which leads to rundown of L-type 
Ca2+ current over time; other Ca2+ conductances (e.g. T-type Ca2+ currents) that have less 
tendency to run-down in the ruptured patch configuration, may then be recorded in 
isolation. The use of pharmacological ion channel blockers to eliminate unwanted 
conductances should be employed with caution unless the specificity of the drugs has been 
thoroughly established.  
Probably most difficult is the isolation of specific K+ currents because many different 
potassium channels are normally expressed in each cell. Several highly specific toxins are 
available for certain subfamilies of potassium channels (hongotoxin and margatoxin for 
Kv1.1, Kv1.2, Kv1.3 (Koschak et al., 1998), hanatoxin for Kv2 (Swartz & MacKinnon, 1995), 
K-dendrotoxin for homo- and heteromeric channels containing Kv1.1 (Robertson et al., 
1996)). These can be used to eliminate a subtype of K+ current or determine the contribution 
of that subtype to the larger mix of K+ currents. It is important to consider that different 
members within a subfamily of K+ channels can combine to form functional heteromeric 
channels, which may vary in their sensitivities to toxins depending on the subunit 
composition (Tytgat et al., 1995; Plane et al., 2005) In some cases, a combination of 
pharmacological approaches and voltage protocols that take advantage of the unique 
biophysical properties of the K+ channels expressed in the cell type under investigation can 
effectively isolate a specific subtype of K+ conductance (see example below).  
Recording a specific current ‘in isolation’ from other currents is never fully achieved, but 
conditions may be established that provide a reasonable signal to noise ratio to evaluate 
contributions of a subset of ion channels. Specific pharmacological ion channel blockers or 
activators may be useful to confirm that the currents measured are largely attributable to a 
particular type of channel, but molecular knockdown approaches are often the best way to 
determine what fraction of the currents measured are mediated by a specific channel 
subtype. When conditions have been optimized for recording isolated currents, the effects of 
the drug on those currents can be tested. 
2.6 Evaluate the actions of the drug of interest at its physiologically or clinically 
relevant concentrations 
An appropriate dose-response range of the drug of interest should be based on 
consideration of physiological or clinically achieved plasma concentrations and doses used 
in vitro from previously published studies. Dose-dependent effects can be evaluated both 
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under physiological ionic conditions as well as under recording conditions that isolate 
specific currents. Stable recording of currents in the absence of drug should be established 
by applying voltage steps or ramps at regular intervals and measuring similar current 
amplitudes for several minutes. Increasing concentrations of the drug are then applied, 
starting at a dose that has little or no effect and increasing in 10-fold or smaller increments to 
at least the maximum clinical or physiological drug concentration. Be aware that repetitive 
drug administration or incrementally increasing doses may induce tachyphylaxis. Applying 
a single dose acutely to a naïve cell may provide the best assessment of the effect of that 
dose of the drug.  
To evaluate whether the presence of the drug changes the biophysical properties of the 
channel, such as its gating kinetics or voltage-dependence of activation, specific voltage 
protocols may be applied when steady-state effects of a particular dose of the drug have 
been achieved. For example, a tail current voltage protocol can be used to evaluate the 
effects of a drug on voltage-dependence of channel activation. This protocol should be 
applied at the end of the control recording (before drug application); two successive voltage 
protocols that yield similar currents establish the stability of the control recording. The same 
successive voltage protocols should then be repeated when measurement of the time course 
of current amplitude indicates that the current amplitude has reached a new plateau in the 
presence of the drug. 
To determine the reversibility of drug effects, it is important to measure the currents during 
drug application and during washout of the drug. It may require tens of minutes to achieve 
a stable reversal of a drug effect and in some cases the effects will not be reversed within a 
practical time frame. Reversibility, when it is achieved, provides convincing evidence that 
the effect measured was specifically due to the drug and not simply due to time-dependent 
changes such as run-up or run-down of currents. It is also important to include vehicle and 
time controls to assure that effects are due to the presence of the drug rather than the time of 
recording or the solvent in which the drug is dissolved.  
Reproducible effects of a drug on the amplitude or biophysical characteristics of a particular 
current in the cultured cell model may provide important clues to the drug’s effect on a 
particular tissue. However, whenever possible, results based on cultured cells should be 
confirmed using freshly isolated cells from the tissue from which the cultured cells were 
derived. The electrophysiological characteristics of the drug-sensitive currents may suggest 
one or more specific ion channel subtypes as the drug targets. Molecular biological 
approaches may then be used to confirm the identity of the drug-sensitive ion channel. 
2.7 Apply molecular biological approaches such as knock-down and overexpression 
as necessary to confirm an ion channel drug target 
As was noted above, cultured cells are often suitable for molecular biological interventions. 
Knock-down of expression of specific ion channels may be achieved by treatment with short 
hairpin RNA (shRNA) or small interfering RNA (siRNA). Alternatively, expression of 
dominant-negative ion channel subunits may specifically abrogate the function of particular 
ion channels. These molecular constructs can be introduced into the cultured cells using 
transfection techniques with appropriate plasmids or by infecting the cells with viral vectors 
engineered to express the constructs. Inactive constructs (e.g. scrambled shRNA) should be 
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used as a control. Biochemical techniques such as RT-PCR or Western blotting and/or 
immunohistochemistry are required to confirm the effectiveness of knock-down.  
Knock-down of expression or function of a specific ion channel can reveal how much that 
channel type contributes to the currents measured and whether a drug effect can be 
attributed to specific actions on that channel type. In electrophysiological recordings, knock-
down of a specific channel type should eliminate the contribution of those channels to the 
currents measured. In other functional assays, loss of the drug effect when the channel is 
knocked down would provide evidence that the functional effects of the drug can be 
specifically attributed to its actions on that channel type. Alternatively, if the effects persist 
even after knockdown of a particular channel then that particular channel is unlikely to be 
the primary drug target.  
Another way to implicate an ion channel as a drug target is to over-express the ion channel 
and test the effects of the drug on the currents. This is best done in the same cellular 
environment known to express that type of ion channel endogenously because the cellular 
environment dictates many properties of ion channels, including regulation by signaling 
pathways that may at times mediate or modulate drug effects. Overexpression typically 
results in much larger currents that can be unambiguously attributed to the overexpressed 
channels. If these channels are direct or indirect targets for the drug, then drug application 
should have effects on the currents similar to the effects observed on native currents. 
Potential pitfalls of these molecular biological strategies include changes in expression or 
function of other molecules that may compensate for the increased or decreased channel 
expression or otherwise alter the measured currents. It is important to keep in mind that 
the effects of drugs on ion currents may not be via a direct interaction with the channel 
itself, but instead mediated by other mechanisms, including activation of cellular 
signaling molecules whose expression may or may not be altered when channel 
expression levels change. 
2.8 Establish a multicellular functional system or animal model for final proof of 
principle 
To determine the physiological significance of drug effects on particular types of ion 
channels, the drug can be tested on in vitro (ex vivo) and/or in vivo functional models. 
Examples of in vitro functional models include the isolated Langendorff heart preparation 
(Skrzypiec-Spring et al., 2007), muscle strips of various origins, aortic or bronchial rings, 
brain slices, lung slices, pressurized artery preparations, etc. These more complex 
experimental systems more closely mimic physiological conditions, but also introduce 
additional factors that may complicate interpretation of drug effects. It is important to 
consider whether changes in tissue function in the presence of a drug can be attributed 
primarily to the drug’s effects on ion channels in a particular cell type. There may be 
multiple effects on multiple cell types within the tissue. 
In vivo drug testing adds a further level of complexity, but it is the ultimate test of how a 
drug will affect whole animal physiology. Many different animal models have been 
developed and are described in the literature. To determine whether an effect of a drug in 
vivo can be attributed to its actions on a specific ion channel, it may be possible to compare 
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its effects with the effects of another drug that is known to have the same or opposite effects 
on that ion channel. 
3. Example: Cyclooxygenase-2 inhibitor effects on vascular smooth muscle 
ion channels 
The following example illustrates how we have employed the approaches described above 
in an attempt to elucidate the mechanisms underlying differential adverse cardiovascular 
risk profiles among clinically used drugs of the same class. Selective cyclooxygenase-2 
(COX-2) inhibitors, such as celecoxib (Celebrex®), rofecoxib (Vioxx®), and diclofenac, are 
non-steroidal anti-inflammatory drugs (NSAIDs) commonly used for the treatment of both 
acute and chronic pain. About five years after celecoxib and rofecoxib were approved for 
use in the United States, rofecoxib (Vioxx®) was voluntarily withdrawn from the market 
because of adverse cardiovascular side effects (Dajani & Islam, 2008). The ensuing 
investigation of the cardiovascular side effects of this drug class revealed differential risk 
profiles, with celecoxib being relatively safe, compared with rofecoxib and diclofenac 
(Cho et al., 2003; Hermann et al., 2003; Aw et al., 2005; Hinz et al., 2006; Dajani & Islam, 
2008). Early reports suggested that these differences might relate to pro-hypertensive 
effects of COX-2 inhibition (Cho et al., 2003; Hermann et al., 2003; Aw et al., 2005; Hinz et 
al., 2006) that were offset by vasodilatory effects of celecoxib (Widlansky et al., 2003; Klein 
et al., 2007). However, the mechanisms underlying the vasodilatory effects of celecoxib 
remained elusive. 
We employed the following strategies to investigate whether celecoxib might exert its 
vasodilatory actions via effects on ion channels in vascular smooth muscle cells (VSMCs). 
Additional details of these studies were published previously (Brueggemann et al., 2009). 
3.1 Vascular smooth muscle cell model 
The embryonic rat aortic A7r5 cell line was chosen as the cell model to compare the effects 
of celecoxib on vascular smooth muscle ion channels with those of rofecoxib and 
diclofenac. The immortalized A7r5 cell line retains a differentiated smooth muscle 
phenotype including expression of L-type and T-type Ca2+ channels (Qar et al., 1988; 
Brueggemann et al., 2005), several types of potassium channels (Kv7.5 (Brueggemann et 
al., 2007), K(Ca)3.1, K(Ca)1.1 (Si et al., 2006) and Kv1.2 (Byron & Lucchesi, 2002)), several 
members of TRPC family of non-selective cation channels (TRPC6, TRPC4, TRPC1, TRPC7 
(Soboloff et al., 2005; Brueggemann et al., 2006; Maruyama et al., 2006)) as well as several 
Gq-coupled receptors (e.g. V1a vasopressin receptors (Thibonnier et al., 1991), 5-HT2 
serotonin receptors (Weintraub et al., 1994), and ETA endothelin-1 receptors (Bucher & 
Taeger, 2002). A7r5 cells proliferate in cell culture until they form a confluent monolayer 
of the cells that are electrically coupled by gap junctions formed by connexins (Cxs) 40 
and 43 (Beyer et al., 1992).  
3.2 Patch clamp mode 
To investigate the vasodilator actions of celecoxib, it was important to consider two types of 
ion channels that are perhaps the most important in determining the contractile state of 
vascular smooth muscle cells: Kv7 channels that determine the resting membrane voltage 
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(Mackie & Byron, 2008), and L-type voltage-gated Ca2+ channels, activation of which 
induces Ca2+ influx, smooth muscle contraction, and vasoconstriction (Jackson, 2000). Both 
of these types of channels are known to be regulated by PIP2 (Suh & Hille, 2008; Suh et al., 
2010). We therefore chose to use the perforated patch-clamp configuration to record currents 
in voltage-clamp mode (200 g/ml amphotericin B in internal solution was used for 
membrane patch perforation).  
3.3 Internal and external solutions 
For the initial test of celecoxib, rofecoxib and diclofenac, total currents were recorded in 
A7r5 cells under approximately physiological ionic conditions. The standard bath solution 
contained (in mM): 5 KCl, 130 NaCl, 10 HEPES, 2 CaCl2, 1.2 MgCl2, 5 D-glucose, pH 7.3. 
Standard internal (pipette) solution contained (in mM): 110 K gluconate, 30 KCl, 5 HEPES, 1 
K2EGTA, 2 Na2ATP, pH 7.2. Osmolality was adjusted to 268-271 mOsm/l with D-glucose. 
3.4 Voltage clamp protocols 
We used a 5s voltage step protocol from -74 mV holding potential to test voltages ranging 
from -94- +36 mV. After each test pulse the voltage was returned to -74 mV for 10 s to allow 
full deactivation before the next voltage step was applied. This protocol enabled us to 
simultaneously record the current-voltage (I-V) relationship for L-type Ca2+ channels (based 
on peak inward currents recorded at the beginning of the voltage steps; see inset on Fig. 1A) 
and for Kv7 channels (based on steady-state outward K+ currents recorded at the end of the 
voltage steps). The evaluation of L-type currents at the beginning of the voltage steps was 
only possible because of the absence of rapidly-activating K+ currents in the voltage range 
used. The long (5s) voltage steps enabled relative isolation of Kv7 currents at the end of the 
voltage steps because Kv7 channels do not inactivate, whereas most other K+ channels do 
inactivate when stepped to a constant activating voltage for 5 s. Representative current 
traces and I-V relationships are shown on Fig. 1A and 1B.  
The I-V voltage protocol requires approximately 4 min to complete all the 5 s voltage steps 
with a 10 s interval between each step. We repeated this three times to determine that the 
currents were stable (the I-V curves were approximately superimposable). When the 
currents were stable we initiated a voltage protocol designed to record the time course of 
drug application. The time course voltage protocol combined 100 ms voltage ramps (from a 
-74 mV holding potential to +36 mV) to record the rapidly-activating Ca2+ current (as the 
peak inward current) followed by 5 s voltage steps to -20 mV to record slowly-activating 
and non-inactivating Kv7 current (measured as the average steady-state current recorded at 
the end of the voltage step; Figure 1C). The time course protocol was applied every 15 s. 
Ca2+ and K+ currents were recorded for at least 5 min before application of celecoxib (10 
μM). Celecoxib was then applied until a stable drug effect was achieved (approximately 15 
min). Then the I-V voltage-step protocol was applied again (twice in succession) to record I-
V relationships of the Ca2+ and K+ channels in the presence of the drug. The time course 
protocol was then re-initiated to monitor the effects of washout of celecoxib. These 
experiments revealed that celecoxib induced a reversible enhancement of Kv7 current and 
inhibition of L-type Ca2+ current—both of these effects could potentially contribute to the 
vasodilatory actions of celecoxib.  
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Fig. 1. Enhancement of K+ current and inhibition of Ca2+ current by celecoxib in A7r5 cells.  
A, representative traces of whole-cell K+  and Ca2+ currents measured in a single A7r5 cell; i, 
control; ii, in the presence of 10 µM celecoxib. Inward Ca2+ currents, activated at the 
beginning of the voltage steps, are shown in insets on an expanded scale for clarity. B, I-V 
curves, corresponding to traces in A, for steady-state K+ current (filled symbols) and peak 
inward Ca2+ current (open symbols) in control (circles), in the presence of 10 µM celecoxib 
(triangles), and after washout of celecoxib (inverted triangles). C, corresponding time course 
of inhibition of the peak inward Ca2+ current and activation of K+ current. Reproduced with 
permission from Brueggemann et al., (2009). 
Similar experiments were conducted to evaluate the effects of other NSAIDs (rofecoxib 
and diclofenac), 2,5-dimethylcelecoxib (a celecoxib analog lacking COX-2 inhibitory 
activity), as well as verapamil (a known inhibitor of L-type Ca2+ channels) and flupirtine 
(a known activator of Kv7.2- Kv7.5 channels) (Brueggemann et al., 2009). The effects of 
these drugs were compared with celecoxib-induced effects on L-type Ca2+ currents and 
Kv7 currents. From these studies it was apparent that neither rofecoxib nor diclofenac 
mimicked celecoxib in its actions on either L-type Ca2+ currents or Kv7 currents; on the 
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other hand, 2,5-dimethylcelecoxib was indistinguishable from celecoxib in its effects 
(Brueggemann et al., 2009). 
3.5 Isolation of L-type Ca2+ currents and Kv7 currents 
To evaluate in more detail the actions of celecoxib on L-type Ca2+ currents and Kv7 currents, 
each type of current was recorded in isolation. To record Ca2+ currents in isolation, a Cs+-
containing internal solution was used (for A7r5 cells, the internal solution contained (in 
mM): 110 Cs aspartate, 30 CsCl, 5 HEPES, 1 Cs-EGTA, pH 7.2). Isolated Ca2+ currents were 
recorded with a 300 ms voltage step protocol from -90 mV holding potential. To isolate Kv7 
currents, 100 μM GdCl3, sufficient to block L- and T-type Ca2+ channels and non-selective 
cation channels, was added to the external solution. Isolated Kv7 currents were recorded 
with the same 5s voltage-step protocol used to record a mix of currents (see above).  
3.6 Effects of celecoxib at therapeutic concentrations 
Celecoxib dose-response curves for L-type Ca2+ currents and Kv7 currents were obtained by 
measuring the currents during successive applications of increasing concentrations of 
celecoxib (ranging from 0.1 µM to 30 µM), each time waiting until the drug effect had 
stabilized before application of the next dose. The celecoxib concentrations selected for dose-
response determinations were based on a ± 10-fold range of mean therapeutic 
concentrations typically achieved in the plasma of patients treated with celecoxib (1-3 µM) 
(Hinz et al., 2006). Our estimated IC50 value for suppression of L-type Ca2+ currents was 8.3 ± 
1.3 µM (Brueggemann et al., 2009). 
To extend the findings to a more physiological model system, the effects of celecoxib were 
also examined using freshly dispersed mesenteric artery myocytes. Celecoxib inhibited Ca2+ 
currents and enhanced Kv7 currents recorded in isolation in mesenteric artery myocytes, 
just as had been observed in A7r5 cells (Brueggemann et al., 2009).  
3.7 Molecular biological approaches to evaluate Kv7.5 as a target of celecoxib 
Kv7 currents measured in A7r5 cells had previously been attributed to Kv7.5 (KCNQ5) 
channel activity based on expression studies and on elimination of the currents by shRNA 
treatment targeting the Kv7.5 (KCNQ5) mRNA transcripts (Brueggemann et al., 2007; Mani 
et al., 2009). To determine whether Kv7.5 was a specific target for celecoxib, we measured 
the effects of celecoxib on overexpressed human Kv7.5 channels, using the A7r5 cells as an 
expression system. Celecoxib robustly enhanced the overexpressed Kv7.5 currents 
(Brueggemann et al., 2009). 
3.8 Functional assays to evaluate how ion channel targeting by celecoxib affects cell 
and tissue physiology 
As noted above, Kv7 channel activity is believed to stabilize negative resting membrane 
voltages in arterial myocytes and thereby opposes the activation of L-type voltage-gated 
Ca2+ channels. The latter mediate Ca2+ influx, smooth muscle contraction, and 
vasoconstriction. Drugs that enhance Kv7 channel activity or that directly inhibit L-type 
Ca2+ activity would therefore be expected to reduce cytosolic Ca2+ concentration, relax the 
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arterial myocytes, and dilate arteries. To test the hypothesis that the effects of celecoxib on 
arterial smooth muscle ion channels contributes to its vasodilatory actions, three different 
functional assays were used: 
a. Arginine-vasopressin (AVP) is a vasoconstrictor hormone that has been shown to 
induce Ca2+ oscillations in confluent monolayers of A7r5 cells. We therefore loaded 
A7r5 cells with the fluorescent Ca2+ indicator fura-2 and examined the effects of 
celecoxib (10 µM) in comparison with rofecoxib (10 µM) on AVP-induced Ca2+ 
oscillations. In support of our hypothesis, celecoxib opposed the actions of the 
vasoconstrictor hormone, essentially abolishing AVP-stimulated Ca2+ oscillations. 
Rofecoxib, in contrast, had no effect (Figure 2A). Inhibition of AVP-stimulated Ca2+ 
oscillations was also observed using known L-type Ca2+ channel blockers or activators 
of Kv7 channels (not shown, but see (Byron, 1996; Brueggemann et al., 2007)). 
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Fig. 2. Functional assays to evaluate celecoxib ion channel actions.  
A, Celecoxib, but not rofecoxib, abolishes AVP-induced Ca2+ oscillations in A7r5 cells. 
Confluent monolayers of fura-2-loaded A7r5 cells were treated with 25 pM AVP (arrow). 
Representative traces show the absence of AVP-induced Ca2+ oscillations with simultaneous 
addition of celecoxib (10 µM, middle) but not with addition of vehicle (top) or rofecoxib (10 
µM, bottom). B, representative traces from rat mesenteric artery pressure myography 
illustrating the inability of 20 µM rofecoxib (top) and 20 µM diclofenac (bottom) to dilate 
arteries preconstricted with 100 pM AVP. Celecoxib (20 µM) fully dilated the same arteries 
when added after either rofecoxib or diclofenac. C, measurement of arteriolar blood flow in 
vivo using intravital microscopy reveals that AVP (100 pM) significantly constricts arterioles 
(top panels) and reduces blood flow (bar graph), but this effect is more than fully reversed 
by the addition of 10 µM celecoxib. Panels A and B reproduced with permission from 
Brueggemann et al., (2009). 
b. The constriction and dilation of arteries can be measured in vitro using pressure 
myography. Small segments of artery are cannulated at either end, pressurized to their 
normal physiological pressure, and maintained at physiological temperatures and ionic 
balance; arterial diameter is monitored continuously by digital image analysis while 
drugs are applied to the bath. We used these methods to test the ability of celecoxib to 
dilate pressurized mesenteric artery segments that were pre-constricted with AVP (100 
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pM). In support of our hypothesis, celecoxib induced concentration-dependent, 
endothelium-independent dilation of pre-constricted mesenteric arteries. Similar effects 
were obtained using known L-type Ca2+ channel blockers or activators of Kv7 channels 
(not shown, but see (Henderson & Byron, 2007; Mackie et al., 2008)). The maximum 
dilatory effect of celecoxib was achieved at a concentration of 20 µM; neither rofecoxib 
nor diclofenac induced significant artery dilation at the same concentration (Figure 2B). 
c. Finally, it is important to evaluate the effects of the drug in an in vivo model. We 
therefore examined the ability of celecoxib to increase blood flow in mesenteric 
arterioles of live anesthetized rats using intravital microscopy and intravenous 
perfusion of fluorescent microspheres. AVP (100 pM) superfused over the exposed 
portion of the mesenteric vasculature induced significant arteriolar constriction and 
reduced blood flow (determined from the velocity of fluorescent microspheres moving 
through the arterioles). Application of celecoxib (10 µM) in addition to AVP more than 
fully restored both arteriolar diameter and blood flow (Figure 2C). 
The combined functional assays provided strong evidence supporting the hypothesis that 
celecoxib, but not other NSAIDs of the same class, exerts vasodilatory effects via combined 
activation of Kv7 potassium channels and inhibition of L-type voltage-gated Ca2+ channels 
in arterial smooth muscle cells. These results may explain the differential risk of adverse 
cardiovascular events in patients taking these different NSAIDs. 
4. Conclusion 
Carefully designed and executed electrophysiological experiments can provide important 
insights into the mechanisms of drug actions, including their off-target effects on specific 
tissues. 
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